Herceptin® Advances Treatment of Early HER2-Positive Breast Cancer
The good news that Herceptin® (trastuzumab) (the world’s first targeted therapy) is now available for many women with early-stage HER2-positive breast cancer, marks a significant advancement in breast cancer management.
According to Edith Perez, M.D., director of Mayo Clinic’s Breast Clinic in Jacksonville, Florida:
“…signifies the importance for women who are newly diagnosed with breast cancer to ensure the care they will receive is the best possible. Women have helped lead a revolution in the care of breast cancer, and now I think all patients should know all that they can do to help direct their care.
“…a million people are diagnosed with breast cancer in this world every year, and many are diagnosed with early disease that is potentially curable. This advance, and all the research continuing on novel therapies based on molecular markers in cancer, provides a brighter future for these patients.”
The use of trastuzumab on early stages of breast cancer has been found beneficial as well as in advanced stage.
In one of four major national studies that examined early use of trastuzumab, they discovered that the drug could change the natural history of the disease. Trastuzumab cut cancer recurrence — the return of the disease by 52 percent, compared to standard therapy.
Read the full report from Mayo Clinic.
Tags: breast-cancer, HER-2, Herceptin, trastuzumabRelated Stories
POSTED IN: on anti-cancer ingredients, on brain cancer
0 opinions for Herceptin® Advances Treatment of Early HER2-Positive Breast Cancer
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: